Metis Global Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Metis Global Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,331	Closed	-$289K	–	769
2025 Q3	$289K	Sell	5,331 -229	-4%	-$13.1K	0.01%	673
2025 Q2	$306K	Sell	5,560 -1,310	-19%	-$77.1K	0.01%	657
2025 Q1	$486K	Buy	6,870 +1,184	+21%	+$79.7K	0.01%	597
2024 Q4	$374K	Buy	5,686 +236	+4%	+$15.8K	0.01%	627
2024 Q3	$383K	Buy	5,450 +480	+10%	+$40.1K	0.01%	624
2024 Q2	$409K	Buy	4,970 +83	+2%	+$6.91K	0.01%	586
2024 Q1	$427K	Buy	4,887 +15	+0.3%	+$1.34K	0.02%	591
2023 Q4	$470K	Sell	4,872 -245	-5%	-$21.7K	0.02%	558
2023 Q3	$453K	Buy	5,117 +214	+4%	+$19K	0.02%	551
2023 Q2	$425K	Buy	4,903 +519	+12%	+$48.8K	0.02%	552
2023 Q1	$426K	Buy	4,384 +1,811	+70%	+$188K	0.03%	517
2022 Q4	$266K	Buy	+2,573	New	+$242K	0.02%	552

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Metis Global Partners's BMRN Position: Q4 2025 in Review

Metis Global Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,331 shares — an estimated $289K sold.

Metis Global Partners first reported a position in BMRN in Q4 2022 and held it in 12 quarters. The position peaked at $486K in Q1 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Metis Global Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Metis Global Partners sold 5,331 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $289K.
Metis Global Partners first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 12 quarters.
Metis Global Partners's BioMarin Pharmaceuticals position peaked at $486K in Q1 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Metis Global Partners's 13F filing for Q4 2025, filed 11 Feb 2026.